Biopharmaceutical company Kamada Ltd. (TASE: KMDA) has completed the registration process in Russia for its KamRho-D IM vaccine to prevent Rh hemolytic disease (hemolysis) in fetuses. The company is working to begin sales in Russia later this year.

Rh hemolytic anemia is caused by incompatibility between a mother and fetus's blood types. Kamada estimates that 15% of women require treatment to prevent this autoimmune condition.

Kamada currently markets KamRho in Israel, and in seven countries in Asia, Africa, and South America. The company estimates the global market for anti Rh immunoglobulin at $250 million a year.

Kamada president and CEO David Tsur said, "Kamada's entry into new large and strategic markets, such as Russia, is very important for the company as part of the expansion of its international business. Registration of the company's products, especially its rabies and anti-Rh vaccines is carried out in parallel with the company's core business - the AAT drug for the treatment of -1 Antitrypsin protein deficiency."

Kamada's share rose 6.6% by mid-afternoon on the TASE today to NIS 25.47, giving a market cap of NIS 619 million.

Published by Globes [online], Israel business news - www.globes-online.com - on February 14, 2010

© Copyright of Globes Publisher Itonut (1983) Ltd. 2010